clinical trial · NCT07533266
Study to Evaluate the Efficacy and Safety of Fexuprazan in Prevention of NSAIDs Induced Peptic Ulcer
Daewoong Pharmaceutical Co. LTD.·phase4·not yet recruiting·n = 360
NSAID (Non-Steroidal Anti-Inflammatory Drug)Fexuprazan 20mgLansoprazole 15 mg placeboLansoprazole 15 mgFexuprazan 20mg placebo
brief summary
The study aims to demonstrate the preventive effect of Fexuprazan 20 mg for peptic ulcer is non-inferior to that of Lansoprazole 15 mg in terms of prevention of peptic ulcer and confirm the safety of Fexuprazan 20 mg.
started
Apr 1, 2026
primary completion
Dec 1, 2027
completion
Dec 1, 2027
last updated
Apr 16, 2026
official title
A Multi-center, Randomized, Double-blind, Parallel-group, Active-controlled, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Fexuclue Tab. in Prevention of NSAIDs-induced Peptic Ulcer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol